GAIASO Theranostics

GAIASO Theranostics is an innovative company focused on transforming the diagnosis and treatment of female cancers through radioligand-based theranostics. Emerging from a collaboration between Navigo Proteins GmbH and PreMIT Pty Ltd (an affiliate of the Melbourne Theranostic Innovation Centre), GAIASO unites a team of globally recognised experts. By leveraging cutting-edge platforms such as Affilin® protein engineering, GAIASO is developing a new generation of theranostic agents. These innovations harness the full potential of radiotherapy through deeper biological understanding of therapeutic targets, tunable biodistribution, and rational combination therapies designed to enhance radiation response. Female cancers are often aggressive and progress to improve outcomes is urgently required. GAIASO’s team is determined to accelerate and deliver life-saving options for more women around the world.